Free Trial

Coloplast A/S (CLPBY) Stock Forecast & Price Target

Coloplast A/S logo
$10.52 +0.02 (+0.16%)
As of 03/28/2025 03:59 PM Eastern

Coloplast A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
1

Based on 3 Wall Street analysts who have issued ratings for Coloplast A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a strong buy rating for CLPBY.

Consensus Price Target

N/A

Get the Latest News and Ratings for CLPBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coloplast A/S and its competitors.

Sign Up

CLPBY Analyst Ratings Over Time

TypeCurrent Forecast
3/30/24 to 3/30/25
1 Month Ago
2/29/24 to 2/28/25
3 Months Ago
12/31/23 to 12/30/24
1 Year Ago
3/31/23 to 3/30/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold
Remove Ads

CLPBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CLPBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Coloplast A/S Stock vs. The Competition

TypeColoplast A/SMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted UpsideN/A18,545.88% Upside19.88% Upside
News Sentiment Rating
Negative News

See Recent CLPBY News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/3/2025Royal Bank of Canada
4 of 5 stars
J. Reynolds-Clar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Moderate Buy
1/28/2025Sanford C. Bernstein
3 of 5 stars
L. Clive
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
12/11/2024UBS Group
4 of 5 stars
G. Doyle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
11/18/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Sell ➝ Hold
9/5/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
7/10/2023DNB Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
6/1/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
5/12/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:25 PM ET.


Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, March 25, 2025. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Coloplast A/S:

  • Coloplast A/S has shown a significant reduction in short interest, dropping by 16.3% in August 2024, indicating increased investor confidence and potentially positive market sentiment.
  • The company operates in a growing industry focused on intimate healthcare products, which is expected to expand as the global population ages and healthcare needs increase.
  • Coloplast A/S offers a diverse range of innovative products, including the latest SenSura Mio ostomy care solutions, which are designed for optimal discretion and fit, appealing to a broad customer base.
  • The current stock price of Coloplast A/S is favorable for entry, providing an opportunity for investors to buy at a potentially undervalued rate compared to its growth prospects.
  • With a strong presence in multiple international markets, including the United States and the United Kingdom, Coloplast A/S is well-positioned to capitalize on global healthcare trends.

Coloplast A/S
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Coloplast A/S for these reasons:

  • Despite the drop in short interest, the overall market volatility can still pose risks to stock performance, particularly in the healthcare sector.
  • Coloplast A/S faces competition from other companies in the surgical appliances and supplies industry, which could impact market share and pricing strategies.
  • The company's reliance on specific product segments, such as ostomy and continence care, may expose it to risks if demand fluctuates or if new technologies emerge.
  • Regulatory changes in healthcare markets can affect product approvals and market access, potentially hindering growth opportunities for Coloplast A/S.
  • Investors should consider the potential for economic downturns that could lead to reduced healthcare spending, impacting sales of Coloplast A/S products.

CLPBY Forecast - Frequently Asked Questions

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There are currently 2 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CLPBY shares.

According to analysts, Coloplast A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Coloplast A/S's stock had 2 upgrades by analysts.

Coloplast A/S has been rated by research analysts at Royal Bank of Canada, and Sanford C. Bernstein in the past 90 days.

Analysts like Coloplast A/S less than other "medical" companies. The consensus rating score for Coloplast A/S is 2.67 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CLPBY compares to other companies.


This page (OTCMKTS:CLPBY) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners